Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates
AssigneeHamilton Civic Hospitals Res Dev., Inc.
InventorsLeslie Berry, Maureen Andrew
Life of this patent
Estimating the term…
Abstract
Novel conjugates of glycosaminoglycans, particularly heparin and dermatan sulfate, and amine containing species and therapeutic uses thereof are described. In particular, mild methods of conjugating heparins to proteins, such as antithrombin III and heparin cofactor II, which provide covalent conjugates which retain maximal biological activity are described. Uses of these conjugates to prevent thrombogenesis, in particular in lung airways, such as found in infant and adult respiratory distress syndrome, and on surfaces in contact with blood are also described.
Claims19
A substantially pure covalent conjugate comprising heparin directly linked to antithrombin III by a covalent linkage wherein said species comprises at least one primary amino group, via a linkage between a primary amino group of the antithrombin III and a terminal aldose residue of the heparin, and pharmaceutically acceptable salts thereof.
A material for use in a medical or prosthetic device, said material comprising a polymer in contact with a covalent conjugate, said covalent conjugate comprising a glycosaminoglycan linked to a species by a covalent linkage, wherein the species comprises at least one primary amino group, and wherein the species is directly covalently linked via said amino group to a terminal aldose residue of the glycosaminoglycan.
A method of reducing the thrombogenicity of a material comprising
- coating the material with ATH.
Dependencies are inferred from the claim text.